Entity type
Company
Filer Snapshot
Xencor Inc
CIK 0001326732. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.
Total filings
140
Latest filing
17 Jun 2026
Industry
Pharmaceutical Preparations
Filing-backed research brief
Start with the SEC data that changes for this CIK
Latest signal: Forms 3/4/5 owner position for INMB. Each card links back to the PortfolioSavvy page where the filing evidence is closest.
Latest 13F portfolio
—
No parsed 13F portfolio row yet.
Browse latest 13FLargest parsed holding
—
Populates from the latest parsed 13F information table.
Open holding13D/G large stake
—
No recent parsed 13D/G stake row for this CIK.
Browse 13D/GInsider / owner context
INMB
03 Sep 2021 · $13.1M
Open owner pageSave this filer page
Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.
Source: SEC Forms 3/4/5
View source filing
4 filed on 17 Jun 2026 for CIK 0001326732.
- Listed symbols
- XNCR on Nasdaq
- Parsed SEC ownership signals
-
Parsed SEC ownership coverage
These bars compare filing-backed value available in each disclosure family. Read them as separate lenses, not as one combined ownership total.
Forms 3/4/5 positions$13.1MReporting-owner positions with enough filing detail to estimate value.
Forms 3/4/5 position value
3/4/5$13.1MEstimated from parsed Forms 3/4/5 when filings include enough share and price data.
Source: Forms 3/4/5Confidence: Estimated when price data is availableLargest linked holdings
Largest issuer positions linked to this CIK across parsed 13F, 13D/G, and Forms 3/4/5 records.
INMBHow to read these SEC ownership signals
- Read each filing family separately: Form 13F, Schedules 13D/G, and Forms 3/4/5 answer different SEC disclosure questions and should not be blended into one ownership total.
- Use 13F values for visible U.S.-listed equity portfolios, 13D/G rows for large beneficial-owner stakes, and Forms 3/4/5 rows for reporting-owner positions and transactions.
- Open the linked research path when you need the filing, CIK, issuer, CUSIP, date, or source trail behind a value.
- SEC industry group
- Pharmaceutical Preparations (Office of Life Sciences)
- Business address
- 465 N. Halstead St., Suite 200, Pasadena, CA, 91107
- Incorporated in
- DE
- Fiscal year end
- 31 December
Ownership signals
CIK-linked ownership evidence from parsed SEC filings.
1 signal
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 2 profile fields available
Filer intelligence
What SEC filings say about Xencor Inc
A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.
Quick read
- Forms 3/4/5 show insider context for INMB worth $13.1M.
SEC source mix
Counts show available parsed rows, not one combined ownership total.
Forms 3/4/5 insider context
INMB
03 Sep 2021 · 10% owner
Latest update
What changed recently for Xencor Inc
Latest financial period: Q1 2026. Open the source-backed page to inspect the fresh filing or facts context.
Update date
06 May 2026
Page type
Company facts
Latest period
Q1 2026
SEC-backed company facts were refreshed from filings filed on 06 May 2026.
Benchmark Context
Benchmark context for this company
Xencor Inc has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.
Compared with
Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.
Why this is notable
Latest financial period: Q1 2026. That gives you a fresh baseline before you compare this company with peers.
- Latest company facts filing date: 06 May 2026.
- Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
- Open the facts page first if you want the cleanest path to verification.
Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.
SEC filing record
CIK 0001326732 filing coverage
Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.
SEC filings
140
First seen
14 Jun 2021
Latest filing
17 Jun 2026
Entity
Company
Observed form types
10-K
10-K/A
10-Q
10-Q/A
3
4
4/A
5
SCHEDULE 13G
SCHEDULE 13G/A
Industry context: Pharmaceutical Preparations.
Latest Filings
Showing the latest 12 of 140 SEC filings for Xencor Inc.
4
4 filing
- Filing date
- 17 Jun 2026
- Reporting date
- 15 Jun 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 17 Jun 2026
- Reporting date
- 15 Jun 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 17 Jun 2026
- Reporting date
- 15 Jun 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 17 Jun 2026
- Reporting date
- 15 Jun 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
10-Q
10-Q filing
- Filing date
- 06 May 2026
- Reporting date
- 31 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 13 Apr 2026
- Reporting date
- 10 Apr 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 09 Mar 2026
- Reporting date
- 05 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 09 Mar 2026
- Reporting date
- 05 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 09 Mar 2026
- Reporting date
- 05 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 09 Mar 2026
- Reporting date
- 05 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 04 Mar 2026
- Reporting date
- 02 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing
4
4 filing
- Filing date
- 04 Mar 2026
- Reporting date
- 02 Mar 2026
- SEC evidence
- Open document Open filing
- Next action
- Verify source filing